APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

TNF Inhibitors for the Treatment of Plaque Psoriasis

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174041650327 December 2025190 pages

Choose your research edition.

Industry ResearchTNF Inhibitors for the Treatment of Plaque Psoriasis Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global TNF Inhibitors for the Treatment of Plaque Psoriasis market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for TNF Inhibitors for the Treatment of Plaque Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for TNF Inhibitors for the Treatment of Plaque Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for TNF Inhibitors for the Treatment of Plaque Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for TNF Inhibitors for the Treatment of Plaque Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of TNF Inhibitors for the Treatment of Plaque Psoriasis include Chia Tai Tianqing Pharmaceutical, Innovent Biologics, Sino Cell Technologies, Samsung Bioepis, Hangzhou Bozhirui Biopharmaceuticals, Hisun Pharmaceuticals, Bio-Thera Solutions, YL Biologics and UCB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global TNF Inhibitors for the Treatment of Plaque Psoriasis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of TNF Inhibitors for the Treatment of Plaque Psoriasis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents TNF Inhibitors for the Treatment of Plaque Psoriasis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the TNF Inhibitors for the Treatment of Plaque Psoriasis market size, projected growth trends, production technologies, key applications, and end-use industries.

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Company

Chia Tai Tianqing Pharmaceutical

Innovent Biologics

Sino Cell Technologies

Samsung Bioepis

Hangzhou Bozhirui Biopharmaceuticals

Hisun Pharmaceuticals

Bio-Thera Solutions

YL Biologics

UCB

Teva

Sandoz

Pfizer

Janssen Biotech

Coherus BioSciences

Celltrion

Boehringer Ingelheim Pharmaceuticals

Biocon Biologics

Amgen

AbbVie

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Type

Adalimumab

Certolizumab pegol

Etanercept

Infliximab

Other

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TNF Inhibitors for the Treatment of Plaque Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of TNF Inhibitors for the Treatment of Plaque Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TNF Inhibitors for the Treatment of Plaque Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the TNF Inhibitors for the Treatment of Plaque Psoriasis market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of TNF Inhibitors for the Treatment of Plaque Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of TNF Inhibitors for the Treatment of Plaque Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of TNF Inhibitors for the Treatment of Plaque Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Trends Table 2. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Drivers Table 3. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Opportunities and Challenges Table 4. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Restraints Table 5. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Manufacturers (2021-2026) Table 7. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Manufacturers Table 9. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers, Product Type & Application Table 13. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global TNF Inhibitors for the Treatment of Plaque Psoriasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Adalimumab Table 17. Major Manufacturers of Certolizumab pegol Table 18. Major Manufacturers of Etanercept Table 19. Major Manufacturers of Infliximab Table 20. Major Manufacturers of Other Table 21. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2026) & (K Units) Table 23. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2027-2032) & (K Units) Table 24. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2021-2026) Table 25. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2027-2032) Table 26. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2026) & (K Units) Table 28. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2027-2032) & (K Units) Table 29. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Type (2021-2026) Table 30. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital and Clinic Table 32. Major Manufacturers of Retail Pharmacies Table 33. Major Manufacturers of Other Table 34. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2026) & (K Units) Table 36. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2027-2032) & (K Units) Table 37. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Application (2021-2026) Table 38. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Application (2027-2032) Table 39. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2026) & (K Units) Table 41. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2027-2032) & (K Units) Table 42. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Application (2021-2026) Table 43. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Application (2027-2032) Table 44. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2021-2026) & (K Units) Table 46. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Region (2021-2026) Table 47. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Forecasted Market Share by Region (2027-2032) Table 49. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 51. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 52. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 54. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 61. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2021-2026) & (US$ Million) Table 63. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2027-2032) & (US$ Million) Table 64. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Region (2021-2026) Table 65. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Region (2027-2032) Table 66. Chia Tai Tianqing Pharmaceutical Company Information Table 67. Chia Tai Tianqing Pharmaceutical Business Overview Table 68. Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 70. Chia Tai Tianqing Pharmaceutical Recent Development Table 71. Innovent Biologics Company Information Table 72. Innovent Biologics Business Overview Table 73. Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 75. Innovent Biologics Recent Development Table 76. Sino Cell Technologies Company Information Table 77. Sino Cell Technologies Business Overview Table 78. Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 80. Sino Cell Technologies Recent Development Table 81. Samsung Bioepis Company Information Table 82. Samsung Bioepis Business Overview Table 83. Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 85. Samsung Bioepis Recent Development Table 86. Hangzhou Bozhirui Biopharmaceuticals Company Information Table 87. Hangzhou Bozhirui Biopharmaceuticals Business Overview Table 88. Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 90. Hangzhou Bozhirui Biopharmaceuticals Recent Development Table 91. Hisun Pharmaceuticals Company Information Table 92. Hisun Pharmaceuticals Business Overview Table 93. Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 95. Hisun Pharmaceuticals Recent Development Table 96. Bio-Thera Solutions Company Information Table 97. Bio-Thera Solutions Business Overview Table 98. Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 100. Bio-Thera Solutions Recent Development Table 101. YL Biologics Company Information Table 102. YL Biologics Business Overview Table 103. YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 105. YL Biologics Recent Development Table 106. UCB Company Information Table 107. UCB Business Overview Table 108. UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 110. UCB Recent Development Table 111. Teva Company Information Table 112. Teva Business Overview Table 113. Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 115. Teva Recent Development Table 116. Sandoz Company Information Table 117. Sandoz Business Overview Table 118. Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 120. Sandoz Recent Development Table 121. Pfizer Company Information Table 122. Pfizer Business Overview Table 123. Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 125. Pfizer Recent Development Table 126. Janssen Biotech Company Information Table 127. Janssen Biotech Business Overview Table 128. Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 130. Janssen Biotech Recent Development Table 131. Coherus BioSciences Company Information Table 132. Coherus BioSciences Business Overview Table 133. Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 135. Coherus BioSciences Recent Development Table 136. Celltrion Company Information Table 137. Celltrion Business Overview Table 138. Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 140. Celltrion Recent Development Table 141. Boehringer Ingelheim Pharmaceuticals Company Information Table 142. Boehringer Ingelheim Pharmaceuticals Business Overview Table 143. Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 145. Boehringer Ingelheim Pharmaceuticals Recent Development Table 146. Biocon Biologics Company Information Table 147. Biocon Biologics Business Overview Table 148. Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 150. Biocon Biologics Recent Development Table 151. Amgen Company Information Table 152. Amgen Business Overview Table 153. Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 155. Amgen Recent Development Table 156. AbbVie Company Information Table 157. AbbVie Business Overview Table 158. AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 160. AbbVie Recent Development Table 161. Key Raw Materials Table 162. Raw Materials Key Suppliers Table 163. TNF Inhibitors for the Treatment of Plaque Psoriasis Distributors List Table 164. TNF Inhibitors for the Treatment of Plaque Psoriasis Customers List Table 165. Research Programs/Design for This Report Table 166. Authors List of This Report Table 167. Secondary Sources Table 168. Primary Sources List of Figures Figure 1. TNF Inhibitors for the Treatment of Plaque Psoriasis Product Image Figure 2. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size (2021-2032) & (US$ Million) Figure 4. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (2021-2032) & (K Units) Figure 5. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 TNF Inhibitors for the Treatment of Plaque Psoriasis Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Adalimumab Image Figure 9. Certolizumab pegol Image Figure 10. Etanercept Image Figure 11. Infliximab Image Figure 12. Other Image Figure 13. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2021-2032) Figure 16. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Type (2021-2032) Figure 19. Hospital and Clinic Image Figure 20. Retail Pharmacies Image Figure 21. Other Image Figure 22. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Application (2021-2032) Figure 25. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Application (2021-2032) Figure 28. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Country (2021-2032) Figure 30. U.S. TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Country (2021-2032) Figure 35. Germany TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Country (2021-2032) Figure 42. China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Country (2021-2032) Figure 50. Brazil TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile TNF Inhibitors for the Treatment of Plaque Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Figure 61. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Figure 63. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. TNF Inhibitors for the Treatment of Plaque Psoriasis Value Chain Figure 69. Manufacturing Cost Structure Figure 70. TNF Inhibitors for the Treatment of Plaque Psoriasis Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Adalimumab
  • Certolizumab pegol
  • Etanercept
  • Infliximab
  • Other
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Innovent Biologics
  • Sino Cell Technologies
  • Samsung Bioepis
  • Hangzhou Bozhirui Biopharmaceuticals
  • Hisun Pharmaceuticals
  • Bio-Thera Solutions
  • YL Biologics
  • UCB
  • Teva
  • Sandoz
  • Pfizer
  • Janssen Biotech
  • Coherus BioSciences
  • Celltrion
  • Boehringer Ingelheim Pharmaceuticals
  • Biocon Biologics
  • Amgen
  • AbbVie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Dynamics
  1. 2.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Trends
  2. 2.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Drivers
  3. 2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Opportunities and Challenges
  4. 2.4 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Restraints
3 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Manufacturers
  1. 3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Manufacturers (2021-2026)
  2. 3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Manufacturers (2021-2026)
  3. 3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers, Product Type & Application
  7. 3.7 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 TNF Inhibitors for the Treatment of Plaque Psoriasis Players Market Share by Revenue in 2025
  11. 3.8.3 2025 TNF Inhibitors for the Treatment of Plaque Psoriasis Tier 1, Tier 2, and Tier 3
4 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Type
  1. 4.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Type Introduction
  2. 4.1.1 Adalimumab
  3. 4.1.2 Certolizumab pegol
  4. 4.1.3 Etanercept
  5. 4.1.4 Infliximab
  6. 4.1.5 Other
  7. 4.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type
  8. 4.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2032)
  10. 4.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2021-2032)
  11. 4.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type
  12. 4.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2032)
  14. 4.3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Type (2021-2032)
5 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Application
  1. 5.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application
  6. 5.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2032)
  8. 5.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Application (2021-2032)
  9. 5.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application
  10. 5.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2032)
  12. 5.3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Application (2021-2032)
6 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region
  1. 6.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2021-2032)
  3. 6.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2021-2026)
  4. 6.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region
  1. 7.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region
  2. 7.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2021-2026)
  4. 7.1.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2027-2032)
  5. 7.1.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032)
  8. 7.2.2 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032)
  11. 7.3.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 8.2 Innovent Biologics
  8. 8.2.1 Innovent Biologics Company Information
  9. 8.2.2 Innovent Biologics Business Overview
  10. 8.2.3 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  12. 8.2.5 Innovent Biologics Recent Developments
  13. 8.3 Sino Cell Technologies
  14. 8.3.1 Sino Cell Technologies Company Information
  15. 8.3.2 Sino Cell Technologies Business Overview
  16. 8.3.3 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  18. 8.3.5 Sino Cell Technologies Recent Developments
  19. 8.4 Samsung Bioepis
  20. 8.4.1 Samsung Bioepis Company Information
  21. 8.4.2 Samsung Bioepis Business Overview
  22. 8.4.3 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  24. 8.4.5 Samsung Bioepis Recent Developments
  25. 8.5 Hangzhou Bozhirui Biopharmaceuticals
  26. 8.5.1 Hangzhou Bozhirui Biopharmaceuticals Company Information
  27. 8.5.2 Hangzhou Bozhirui Biopharmaceuticals Business Overview
  28. 8.5.3 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  30. 8.5.5 Hangzhou Bozhirui Biopharmaceuticals Recent Developments
  31. 8.6 Hisun Pharmaceuticals
  32. 8.6.1 Hisun Pharmaceuticals Company Information
  33. 8.6.2 Hisun Pharmaceuticals Business Overview
  34. 8.6.3 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  36. 8.6.5 Hisun Pharmaceuticals Recent Developments
  37. 8.7 Bio-Thera Solutions
  38. 8.7.1 Bio-Thera Solutions Company Information
  39. 8.7.2 Bio-Thera Solutions Business Overview
  40. 8.7.3 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  42. 8.7.5 Bio-Thera Solutions Recent Developments
  43. 8.8 YL Biologics
  44. 8.8.1 YL Biologics Company Information
  45. 8.8.2 YL Biologics Business Overview
  46. 8.8.3 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  48. 8.8.5 YL Biologics Recent Developments
  49. 8.9 UCB
  50. 8.9.1 UCB Company Information
  51. 8.9.2 UCB Business Overview
  52. 8.9.3 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  54. 8.9.5 UCB Recent Developments
  55. 8.10 Teva
  56. 8.10.1 Teva Company Information
  57. 8.10.2 Teva Business Overview
  58. 8.10.3 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  60. 8.10.5 Teva Recent Developments
  61. 8.11 Sandoz
  62. 8.11.1 Sandoz Company Information
  63. 8.11.2 Sandoz Business Overview
  64. 8.11.3 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  66. 8.11.5 Sandoz Recent Developments
  67. 8.12 Pfizer
  68. 8.12.1 Pfizer Company Information
  69. 8.12.2 Pfizer Business Overview
  70. 8.12.3 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  72. 8.12.5 Pfizer Recent Developments
  73. 8.13 Janssen Biotech
  74. 8.13.1 Janssen Biotech Company Information
  75. 8.13.2 Janssen Biotech Business Overview
  76. 8.13.3 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  78. 8.13.5 Janssen Biotech Recent Developments
  79. 8.14 Coherus BioSciences
  80. 8.14.1 Coherus BioSciences Company Information
  81. 8.14.2 Coherus BioSciences Business Overview
  82. 8.14.3 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  84. 8.14.5 Coherus BioSciences Recent Developments
  85. 8.15 Celltrion
  86. 8.15.1 Celltrion Company Information
  87. 8.15.2 Celltrion Business Overview
  88. 8.15.3 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  90. 8.15.5 Celltrion Recent Developments
  91. 8.16 Boehringer Ingelheim Pharmaceuticals
  92. 8.16.1 Boehringer Ingelheim Pharmaceuticals Company Information
  93. 8.16.2 Boehringer Ingelheim Pharmaceuticals Business Overview
  94. 8.16.3 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  96. 8.16.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
  97. 8.17 Biocon Biologics
  98. 8.17.1 Biocon Biologics Company Information
  99. 8.17.2 Biocon Biologics Business Overview
  100. 8.17.3 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  102. 8.17.5 Biocon Biologics Recent Developments
  103. 8.18 Amgen
  104. 8.18.1 Amgen Company Information
  105. 8.18.2 Amgen Business Overview
  106. 8.18.3 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  108. 8.18.5 Amgen Recent Developments
  109. 8.19 AbbVie
  110. 8.19.1 AbbVie Company Information
  111. 8.19.2 AbbVie Business Overview
  112. 8.19.3 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  114. 8.19.5 AbbVie Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Value Chain Analysis
  2. 9.1.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 TNF Inhibitors for the Treatment of Plaque Psoriasis Production Mode & Process
  6. 9.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Distributors
  9. 9.2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst